← ALK-Abelló A/S (ALK-B.CO) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
ALK-Abelló A/S (ALK-B.CO)
Pharmaceutical Preparations · market cap $6.4B · as of 2026-07-14
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
20
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
ALK-Abelló A/S (ALK-B.CO) is a Danish specialty pharmaceutical company with 2,759 employees and an ~$8.1B market cap, focused exclusively on allergy immunotherapy (AIT). The company operates a broad pipeline of sublingual tablets, subcutaneous injections, and drops across house dust mite (HDM), grass pollen, tree pollen, and other allergen categories, with the nearest binary event being a Phase 3 readout for the HDM SLIT-tablet (12 SQ-HDM) estimated around September 6, 2026.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Dupixent® | Phase 2 | Allergic Rhinoconjunctivitis |
| ALK HDM tablet | Phase 3 | Asthma |
| MK-8237 6 DU | Phase 2 | Rhinitis, Allergic, Perennial |
| AVANZ Salsola | Phase 2 | Allergic Rhinoconjunctivitis Due to Salsola Kali Pollen |
| ALK Grass tablet - use of compliance device | Phase 3 | Allergy |
| AVANZ Phleum pratense 15,000 SQ+ | Phase 2 | Grass Pollen Induced Allergic Rhinoconjunctivitis |
| Sublingual allergy immunotherapy tablet | Phase 3 | Allergic Rhinitis Due to Dermatophagoides Farinae |
| AVANZ Phleum pratense | Phase 3 | Allergic Rhinoconjunctivitis |
| Grass (Phleum pratense) pollen allergen extract | Phase 3 | Rhinitis Allergic |
| AIT Tablet | Phase 3 | House Dust Mite Allergy |
| Specific allergen immunotherapy | Phase 2 | Cat Allergy |
| Ambrosia artemisiifolia allergen extract (Amb a 1-U) | Phase 3 | Rhinitis, Allergic |
| ALK Grass tablet | Phase 3 | Allergy |
| Grazax + Aerius | Phase 3 | Allergic Rhinoconjunctivitis |
| Loratadine 10 mg Rescue Treatment | Phase 3 | Rhinoconjunctivitis |
| SCH 39641 | Phase 3 | Allergy |
| Allergy vaccination (Alutard SQ) | Phase 3 | Allergy |
| subcutaneous immunotherapy | Phase 3 | Atopic Dermatitis |
| Pangramin SLIT HDM mix. | Phase 3 | Allergic Rhinitis |
| HDM SLIT-tablet | Phase 3 | Allergic Rhinitis |
Price & technical context
3-month
-16.4%
6-month
-1.7%
12-month
-1.6%
52-wk range
$192.30–$270.40
vs 50-day MA
-3.3%
vs 200-day MA
-10.3%
Realized vol
26.9%
Max drawdown
-28.9%
Daily closes through 2026-10-05. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ALK-B.CO (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.